Legal Action
Page 1 • 4 itemsTrack global pharma legal actions, patent litigation, regulatory challenges, and IP disputes impacting drug development and market access. Stay informed.
Atara Biotherapeutics Faces Securities Class Action Lawsuit with May 2026 Deadline for Lead Plaintiff Applications
Atara Biotherapeutics investors with losses exceeding $100K can join securities class action lawsuit. Lead plaintiff deadline set for May 22, 2026.
Aquestive Therapeutics Faces Class Action Lawsuit Over Alleged FDA Application Misrepresentations
Aquestive Therapeutics investors who purchased AQST stock between June 2025 and January 2026 face May 4 deadline to join class action lawsuit over alleged FDA misstatements.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims
ImmunityBio faces securities lawsuit after FDA warning letter regarding executive claims about lead immunotherapy drug Anktiva, impacting investor confidence.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Ankt Drug Claims
ImmunityBio faces securities lawsuit after FDA warning letter regarding executive claims about lead biologic Ankt, affecting investors from Jan-Mar 2026.